Immix Biopharma, Inc. (NASDAQ: IMMX) is a Healthcare company (Biotechnology) with a market capitalization of $603M. The Maz Rating grades it against the other companies in its sector.
Immix Biopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.20, Immix Biopharma, Inc. trades at 1.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -24.9%, return on invested capital of -14.9% and a free cash flow yield of -7.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 33.72. Over the past 52 weeks the share price ranged from $3.78 to $15.10, with a beta of 0.11.
Immix Biopharma, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Immix Biopharma, Inc. (IMMX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.01% / 30% · (Cash+Inv) / Mkt Cap (36m) 50.1% / 30% · Interest income / Revenue 201869100.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.01% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 49.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 201869100.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.01% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 49.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 201869100.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.01% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 201869100.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.03% / 33.33% · (Cash+ST Inv) / Total Assets 97.2% / 33.33% · (Cash+Recv) / Total Assets 97.2% / 33.33% · Interest income / Revenue 201869100.0% / 5% | Fail |
No. As of September 2026, Immix Biopharma, Inc. (IMMX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Immix Biopharma, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 201869100.0% of each dividend: Immix Biopharma, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.